Skip to main content

Table 1 Model parameters, sources, and distributions used in the probabilistic analysis

From: Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis

Parameter Value Distribution Source
Probabilities
 Serious adverse event (BREN+AVD) 0.429 Beta Connors et al. (2018) [10]
 Serious adverse event (ABVD) 0.270 Beta Connors et al. (2018) [10]
 Treatment discontinuation (BREN+AVD) 0.133 Beta Connors et al. (2018) [10]
 Treatment discontinuation (ABVD) 0.159 Beta Connors et al. (2018) [10]
 Mortality on treatment (BREN+AVD) 0.013 Beta Connors et al. (2018) [10]
 Mortality on treatment (ABVD) 0.019 Beta Connors et al. (2018) [10]
 Progression/relapse while in complete remission (BREN+AVD) Time Dep Beta Connors et al. (2018) [10]
 Mortality in complete remission (BREN+AVD) Time Dep Beta Connors et al. (2018) [10]
 Progression/relapse while in complete remission (ABVD) Time Dep Beta CLC
 Mortality in complete remission (ABVD) Time Dep Beta CLC
 Eligible for ASCT (BREN+AVD or ABVD) 0.8 Beta Expert Opinion
 Mortality in progression/relapse (ABVD) Time Dep Beta Vivani et al. (2011) [12]
 Mortality in progression/relapse (BREN+AVD) Time Dep Beta Vivani et al. (2011) [12]
 Successful ASCT 0.5 Beta Expert Opinion
 Progression/relapse post-ASCT (BREN+AVD) Time Dep Beta CLC
 Progression/relapse post-ASCT (ABVD) Time Dep Beta CLC
 Mortality post-ASCT progression/relapse (BREN+AVD or ABVD) Time Dep Beta Chen et al. (2016) [13]
Costs
 Cost BREN+AVD $116,160 Gamma Canadian list price for six cycles
 Cost ABVD $12,701 Gamma Canadian list price for six cycles
 PET scan $1877 Gamma Cerci et al. (2010) [14]
 Cost of adverse event (ABVD or BREN+AVD) $12,036 Gamma Wong et al. (2018) [15]
 ASCT $67,723 Gamma Bloomstein et al. (2012) [16]
 Salvage chemotherapy for non-responders $140,800 Gamma Canadian list price for six cycles
Utility values
 Receiving treatment (ABVD or BREN+AVD) 0.71 Beta Swinburn et al. (2015) [17]
 Complete remission 0.91 Beta Swinburn et al. (2015) [17]
 Adverse event 0.59 Beta Swinburn et al. (2015) [17]
 Progressive disease 0.38 Beta Swinburn et al. (2015) [17]
Model details
 Cycle length 6 months   Assumed
 Time horizon 15 years   Assumed
 Cost year 2018   Assumed
 Discount rate: costs 1.5%   Assumed
 Discount rate: effects 1.5%   Assumed
  1. Time Dep time-dependent transition probability. CLC Centre for Lymphoid Cancer
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us